Navigation Links
PLC Systems Reports Second Quarter 2011 Results
Date:8/12/2011

oss from continuing operations

(800)(869)(1,549)(2,088)Other expense:Interest expense

(115)--(161)--Financing costs associated with convertible notes

----(530)--Change in fair value of warrant liabilities

372--(1,104)--Change in fair value of convertible notes

2--(2,216)--Total other expense

259--(4,011)--Net loss from continuing operations

(541)(869)(5,560)(2,088)Discontinued operations:Income from discontinued operations

--670531,328Gain on sale of discontinued operations

----1,179--Net income from discontinued operations

--6701,2321,328Net loss

$  (541)$  (199)$(4,328)$  (760)Net loss per weighted average share, basic and diluted:From loss on continuing operations attributable
 to common stockholders

$(0.02)$(0.03)$  (0.18)$(0.07)From income on discontinued operations

--0.020.000.04From gain on sale of discontinued operations

----0.04--Net loss attributable to common stockholders
per weighted average share, basic and diluted

$ (0.02)$ (0.01)$  (0.14)$(0.03)Weighted average shares outstanding:Basic and diluted

30,35130,35130,35130,351CONDENSED BALANCE SHEET(In thousands, except per share data)

(Unaudited)June 30,
2011December 31,
2010Cash and cash equivalents$4,059$1,324Total current assets4,7443,102Total assets4,9523,315T
'/>"/>

SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ruby+Associates Completes Latest Mercy Health Systems Design-Build Project
2. Scientific Presentations at 2011 AAPM/COMP Meeting Highlight TrueBeam® and RapidArc® Radiotherapy Systems From Varian Medical Systems
3. Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems
4. Researchers Find RapidArc® Radiotherapy from Varian Medical Systems Can Quickly and Accurately Deliver Total Marrow Irradiation (TMI) Treatments for Patients with Blood Cancers
5. China Medical Technologies and Leica Microsystems Announce Collaboration
6. David J. Illingworth Appointed to Board of Directors for Varian Medical Systems
7. South Florida Radiation Oncology on the Forefront of Cancer Treatment with the TrueBeam™ Radiotherapy System from Varian Medical Systems
8. Varian Medical Systems to Offer CIVCO Medical Solutions Body Pro-Lok™ for SBRT
9. Streamline Health Announces Two Clients Have Contracted for Multiple Integrations to Their Epic Systems
10. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
11. Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... Brittenford Systems, a ... and other growing businesses across the United States, has announced that it has ... the fifth consecutive year. , Based on company revenue and number of employees, ...
(Date:6/29/2015)... Church, VA (PRWEB) , ... June 29, 2015 ... ... Optimizing Interaction with Medical Devices , **FDAnews Webinar**, July 16, 2015 — 1:30 ... manufacturers to help ensure the application of human factors engineering to the design ...
(Date:6/29/2015)... ... ... across the country give their coworkers and families gifts all the time. From holiday exchanges ... often do coworkers donate “life” to the husband of a coworker? For one VA employee, ... told me her husband was on a donor list,” Glenshaw resident Kathi Dahl said. “I ...
(Date:6/29/2015)... ... June 29, 2015 , ... Two multicounty ... C.R. Bard, Inc. and Ethicon, Inc. continue to move forward in New Jersey’s ... Conference is to be convened on Thursday, July 23rd at 12:00 p.m. (In ...
(Date:6/29/2015)... (PRWEB) , ... June 29, 2015 , ... ... to healthcare providers for patients with certain neuropsychiatric and chronic pain conditions, has ... and CEO. , The appointments include: Peter Donato, Senior Vice President, Chief Financial ...
Breaking Medicine News(10 mins):Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 2Health News:Brittenford Systems Celebrates Fifth Consecutive Year on Bob Scott Insights Top 100 VARs 3Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 2Health News:FDAnews Announces Human Factors and Usability Studies: Understanding and Optimizing Interaction with Medical Devices Webinar, July 16, 2015 3Health News:VA Pittsburgh Employee Donates Kidney to Coworker’s Spouse 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 2Health News:Assurex Health Names Executives to Posts as CFO, CMO and VP/Clinical Operations 3
... a bewildering array of regulatory DNA sequences interacting with a ... which genes are active when and where. Understanding how ... past decades but we are now starting to make significant ... how the entire complexity evolves to give differences in the ...
... giving up smoking after a programme involving sending motivational and ... months. , The findings of the txt2stop trial, which was ... and funded by the Medical Research Council, are published in ... innovative approach to the deadly problem of smoking, which is ...
... Current or heavy smokers who were screened with low-dose spiral ... deaths from lung cancer than did those who were screened ... clinical trial that involved more than 53,000 people. The ... in individuals at high risk of developing lung cancer to ...
... 29, 2011) A new treatment option may soon ... published in the July issue of The Journal ... that combined positron emission tomography and X-ray computed tomography ... refractory or relapsed high-risk neuroblastoma for treatment with a ...
... News) -- A new study reveals that 90 percent of ... started smoking, drinking or using drugs before they were 18 ... Americans who began using any addictive substance before age 18 ... using an addictive substance when they were 21 or older. ...
... cancer has provided the most comprehensive and integrated view of ... adenocarcinoma tumors from 500 patients were examined by The Cancer ... the June 30, 2011, issue of Nature . ... cancer, accounting for about 85 percent of all ovarian cancer ...
Cached Medicine News:Health News:Many a mickle makes a muckle: How changes in animals' size and shape arise 2Health News:Text message support for smokers doubles quit rates 2Health News:Screening with low-dose spiral CT scanning reduces lung cancer deaths by 20 percent 2Health News:Screening with low-dose spiral CT scanning reduces lung cancer deaths by 20 percent 3Health News:New therapy for childhood neuroblastoma proves feasible and safe 2Health News:Addiction Starts Early in American Society, Report Finds 2Health News:Addiction Starts Early in American Society, Report Finds 3Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 2Health News:The Cancer Genome Atlas completes detailed ovarian cancer analysis 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: